Randomized multicenter trial of 3 weekly cabazitaxel versus weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (MBC).
Amit Bahl(At Bristol), William Wilson(Cancer Research UK), Duncan Wheatley(National Health Service), Mark Verrill(Newcastle upon Tyne Hospitals NHS Foundation Trust), Pavel Bezecny(Clinical Trial Investigators), Jeremy Braybrooke(University Hospitals Bristol NHS Foundation Trust), Peter Stephens(Royal Devon & Exeter NHS Foundation Trust), Rebecca Bowen, Sidharth Dubey(Derriford Hospital), Mark Churn(Guy's and St Thomas' NHS Foundation Trust), Alison Markham(University Hospitals Bristol NHS Foundation Trust), Alicia Bravo(University Hospitals Bristol NHS Foundation Trust), Simon Waters(Velindre Cancer Centre), Jessica Ball(University Hospitals Bristol NHS Foundation Trust), S.K. Pearson(University Hospitals Bristol NHS Foundation Trust), Emily Foulstone(University Hospitals Bristol NHS Foundation Trust), Janine Mansi(Guy's and St Thomas' NHS Foundation Trust), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Pippa Riddle(Charing Cross Hospital), S. Spensley(Musgrove Park Hospital)
Cited by 2
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
|BMC Cancer|2010|755